Publications by authors named "Naoki Shingu"

Claim this Profile
T
Turtle Study: A Phase 2 Study of Durvalumab Plus Carboplatin and Etoposide in Elderly Patients With Extensive-Stage SCLC (LOGiK 2003).
Hidenobu Ishii, Koichi Azuma, Yuta Yamanaka, Hiroshige Yoshioka, Yukihiro Toi, Naoki Shingu

JTO Clin Res Rep· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of durvalumab re-administration after moderate symptomatic pneumonitis in locally advanced non-small cell lung cancer.
Yosuke Kakiuchi, Koichi Saruwatari, Takaaki Tokito, Toyohisa Iriki, Jun Iwakawa, Naoki Shingu

Lung Cancer· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Efficacy and Safety of Durvalumab Administration Following Chemoradiotherapy in Elderly Patients With Unresectable Locally Advanced Nonsmall Cell Lung Cancer: A Multicenter, Retrospective Study.
Yosuke Kakiuchi, Koichi Saruwatari, Kenta Murotani, Takaaki Tokito, Toyohisa Iriki, Naoki Shingu

Clin Lung Cancer· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Durvalumab with etoposide and carboplatin for patients with extensive-stage small cell lung cancer and interstitial lung disease: A multicenter, open-label prospective trial.
Ryota Shibaki, Daichi Fujimoto, Eisaku Miyauchi, Yoko Tsukita, Ichiro Nakachi, Naoki Shingu

Lung Cancer· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II study of durvalumab (MEDI 4736) plus carboplatin and etoposide in elderly patients with extensive stage small cell lung cancer: Study protocol of turtle study (LOGIK 2003).
Hidenobu Ishii, Koichi Azuma, Takayuki Shimose, Hiroshige Yoshioka, Takayasu Kurata, Naoki Shingu

Thorac Cancer· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Histologic transformation of epidermal growth factor receptor-mutated lung cancer.
Daichi Fujimoto, Hiroaki Akamatsu, Takeshi Morimoto, Kazushige Wakuda, Yuki Sato, Naoki Shingu

Eur J Cancer· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical phenotypes from fatal cases of acute respiratory distress syndrome caused by pneumonia.
Kazuya Ichikado, Kodai Kawamura, Takeshi Johkoh, Kiminori Fujimoto, Ayumi Shintani, Naoki Shingu

Sci Rep· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical outcomes and predictive value of programmed cell death-ligand 1 expression in response to anti-programmed cell death 1/ligand 1 antibodies in non-small cell lung cancer patients with performance status 2 or greater.
Takayuki Jodai, Koichi Saruwatari, Tokunori Ikeda, Eiji Moriyama, Kosuke Kashiwabara, Naoki Shingu

Int J Clin Oncol· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effects of switching EGFR-TKI treatments for non-small cell lung cancer because of adverse events.
Yoshihiko Sakata, Kodai Kawamura, Naoki Shingu, Shigeo Hiroshige, Yuko Yasuda

Asia Pac J Clin Oncol· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparisons between tumor burden and other prognostic factors that influence survival of patients with non-small cell lung cancer treated with immune checkpoint inhibitors.
Yoshihiko Sakata, Kodai Kawamura, Kazuya Ichikado, Naoki Shingu, Yuko Yasuda

Thorac Cancer· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The association between tumor burden and severe immune-related adverse events in non-small cell lung cancer patients responding to immune-checkpoint inhibitor treatment.
Yoshihiko Sakata, Kodai Kawamura, Kazuya Ichikado, Naoki Shingu, Yuko Yasuda

Lung Cancer· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Upfront Cranial Radiotherapy Followed by Erlotinib Positively Affects Clinical Outcomes of Epidermal Growth Factor Receptor-mutant Non-small Cell Lung Cancer With Brain Metastases.
Koichi Saruwatari, Tokunori Ikeda, Sho Saeki, Naoki Shingu, Kosuke Imamura

Anticancer Res· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erlotinib plus bevacizumab as an effective treatment for leptomeningeal metastases from EGFR mutation-positive non-small cell lung cancer.
Yoshihiko Sakata, Kodai Kawamura, Naoki Shingu, Kazuya Ichikado

Lung Cancer· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of azithromycin in sepsis-associated acute respiratory distress syndrome: a retrospective study and propensity score analysis.
Kodai Kawamura, Kazuya Ichikado, Makoto Takaki, Yoshihiko Sakata, Yuko Yasuda, Naoki Shingu

Springerplus· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis